A Real-world Clinical Study on Effectiveness and Safety of Long-term TAF Treatment in Chronic Hepatitis B Patients in China
Phase of Trial: Phase IV
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Tenofovir alafenamide (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms TRUE
- 25 Nov 2019 Status changed from not yet recruiting to recruiting.
- 25 Nov 2019 Planned End Date changed from 1 Jun 2023 to 1 Sep 2023.
- 25 Nov 2019 Planned primary completion date changed from 31 Dec 2022 to 1 May 2023.